Aldeyra Therapeutics to Present at the Stifel 2016 Healthcare Conference
(firmenpresse) - LEXINGTON, MA -- (Marketwired) -- 11/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at the Lotte New York Palace Hotel, New York.
Stifel 2016 Healthcare Conference
Wednesday, November 16, 2016
2:55 PM ET
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra''s lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra''s product candidates have not been approved for sale in the U.S. or elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.11.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 1468846
Anzahl Zeichen: 3587
contact information:
Contact person:
Town:
LEXINGTON, MA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Aldeyra Therapeutics to Present at the Stifel 2016 Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Aldeyra Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
